Abstract

BackgroundRA flares are common and disabling. They are described in terms of worsening inflammation but pain and inflammation are often discordant. To inform treatment decisions, we investigated whether inflammatory and pain flares are discrete entities.MethodsPeople from the Early RA Network (ERAN) cohort were assessed annually up to 11 years after presentation (n = 719, 3703 person-years of follow up). Flare events were defined in 2 different ways that were analysed in parallel; DAS28 or Pain Flares. DAS28 Flares satisfied OMERACT flare criteria of increases in DAS28 since the previous assessment (≥1.2 points if active RA or ≥ 0.6 points if inactive RA). A ≥ 4.8-point worsening of SF36-Bodily Pain score defined Pain Flares. The first documented episode of each of DAS28 and Pain Flare in each person was analysed. Subgroups within DAS28 and Pain Flares were determined using Latent Class Analysis. Clinical course was compared between flare subgroups.ResultsDAS28 (45%) and Pain Flares (52%) were each common but usually discordant, with 60% of participants in DAS28 Flare not concurrently in Pain Flare, and 64% of those in Pain Flare not concurrently in DAS28 Flare. Three discrete DAS28 Flare subgroups were identified. One was characterised by increases in tender/swollen joint counts (14.4%), a second by increases in symptoms (13.1%), and a third displayed lower flare severity (72.5%). Two discrete Pain Flare subgroups were identified. One occurred following low disease activity and symptoms (88.6%), and the other occurred on the background of ongoing active disease and pain (11.4%). Despite the observed differences between DAS28 and Pain Flares, each was associated with increased disability which persisted beyond the flare episode.ConclusionFlares are both common and heterogeneous in people with RA. Furthermore our findings indicate that for some patients there is a discordance between inflammation and pain in flare events. This discrete flare subgroups might reflect different underlying inflammation and pain mechanisms. Treatments addressing different mechanisms might be required to reduce persistent disability after DAS28 and Pain Flares.

Highlights

  • 28 joint disease activity score (DAS28) Flares were identified in 45% and Pain Flares in 52% of participants (Table 1)

  • The seropositive status of participants were similar in the overall eligible population and those recorded as having DAS28 Flares and Pain Flares (Table 1)

  • Our findings indicate that DAS28-defined flares alone might not represent the breadth of flare experience in rheumatoid arthritis (RA) and an alternative, patient-centred classification of RA Pain Flare identifies episodes that differ from DAS28 Flares

Read more

Summary

Introduction

They are described in terms of worsening inflammation but pain and inflammation are often discordant. The OMERACT initiative classified RA flare based upon increases in the 28 joint disease activity score, DAS28 [3]. DAS28 is widely used in clinics, has validity for treatment targets and shaping long-term outcomes [4]. These DAS28-based flare criteria exceed 70% specificity and sensitivity, compared with the judgement of the patient [3]. They showed sensitivity of 88–100%, and specificity of 57–65% for detecting investigator-defined flares and after biologic discontinuation in 1 clinical trial [5]. RA flares are commonly treated with anti-inflammatory glucocorticosteroids and changes to disease modifying anti-rheumatic drugs (DMARDs)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call